Lung transplantation: A treatment option in end-stage lung disease
In the past five years, the number of lung transplantations carried out has increased by about 20%. In the end stage of various lung diseases, transplantation is the last remaining option for treatment, and it can both prolong life and improve its quality. Marc Hartert and colleagues have studied how patients do after a lung transplant, and their review appears in the current edition of the Deutsches Ärzteblatt International.What they found is that deaths in the 90 days after an operation for lung transplantation have gone down over the past 25 years from 19.4% to 10%.
650,000 renal, hepatic, and cardiothoracic (heart and/or lung) transplants have been performed in the U.S. since 1988, with UNOS reporting a 20% increase in transplants between 2012 through 2016. The immunosuppression vital to maintaining graft survival comes with a 65-200X greater frequency of SCC compared to the non-transplant population. These SCC exhibit more aggressive behavior, withincreased morbidity and mortality. The aim of this study was to investigate the impact of rejection on the incidence and presentation of SCC.
A LITTLE girl born without a diaphragm has become the first person in Britain to have one built by medics using pig skin. Eve Phillipson, two, had endured two failed operations to rebuild the layer of muscle separating the lungs and the stomach when surgeons made a third and final attempt.
Conclusion: IT following lung and liver transplantation, with injection of islets into a transplanted organ, is feasible. It improves C-peptide secretion, decreases insulin needs, and lowers HbA1c.Horm Res Paediatr
Organs donated from people infected with hepatitis C can be safely transplanted, and any transmission of the virus can be treated with antiretrovirals, new research shows.Medscape Medical News
Conditions: Idiopathic Pulmonary Fibrosis; Emphysema or COPD Interventions: Biological: CD3/CD19 negative hematopoietic stem cells; Drug: Rituximab; Drug: Alemtuzumab; Drug: Fludarabine; Drug: Thiotepa; Drug: G-CSF; Drug: Hydroxyurea Sponsor: Paul Szabolcs Not yet recruiting
Condition: Lung Transplant Rejection Intervention: Device: photopheresis Sponsors: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Italian Cystic Fibrosis Research Foundation Not yet recruiting
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...